Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

34.480
+0.4801.41%
Volume:2.74M
Turnover:94.28M
Market Cap:209.09B
PE:31.70
High:34.680
Open:34.000
Low:33.420
Close:34.000
52wk High:43.939
52wk Low:27.882
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:0.53
T/O Rate:0.05%
Dividend:0.43
Dividend Rate:1.25%
EPS(LYR):1.088
ROE:19.40%
ROA:9.08%
PB:4.73
PE(LYR):31.70
PS:11.24

Loading ...

GSK Flags Availability of Hansoh Pharma Update on Ris-rez Phase III China Trial Results

Reuters
·
Jul 10

Hansoh Pharma Says Hs-20093 Meets Overall Survival Endpoint in Phase 3 Small Cell Lung Cancer Trial

Reuters
·
Jul 10

Movement Alert|Hansoh Pharmaceutical Rises 3.08% in Regular Trading, Innovation Drug Payment Reform Catalyzes Sector-Wide Rally

Market Focus
·
Jul 10

Hansoh Pharmaceutical Group Stock Slips 3.0% in Hong Kong

Dow Jones
·
Jul 09

Movement Alert|Hansoh Pharmaceutical Falls 3.05% in Regular Trading, Trading at HK$31.2

Market Focus
·
Jul 09

Movement Alert|Hansoh Pharmaceutical Rises 3.07% in Regular Trading, Innovative Drug Pipeline Catalysts Continue Amid Sector Rebound

Market Focus
·
Jul 08

Hansoh Pharmaceutical Group Stock Sheds 4.2% in Hong Kong

Dow Jones
·
Jul 07

Movement Alert|Hansoh Pharmaceutical Falls 3.24% in Regular Trading, Pharmaceutical Sector Retreats After Prior Session Gains

Market Focus
·
Jul 07

Movement Alert|Hansoh Pharma Rises 3.74% in Regular Trading, HS-20136-2 Clinical Trial Approvals Continue to Drive Momentum Amid Pharma Sector Strength

Market Focus
·
Jul 06

Hansoh Pharmaceutical Group (SEHK:3692) Wins Trial Approval, Is It Fully Priced?

Simply Wall St.
·
Jul 05

Hansoh Pharma Keeps Share Base Steady at 6.06 Billion in June, Details HKD 4.68 Billion Convertible Bonds

Bulletin Express
·
Jul 03

Movement Alert|Hansoh Pharmaceutical Rises 4.41% in Regular Trading, HS-20136-2 Injection Receives Two Clinical Trial Approvals from NMPA

Market Focus
·
Jul 03

Hansoh Pharmaceutical Receives Dual NMPA Approvals for HS-20136-2 Injection Trials in Diabetes and Weight Management

Bulletin Express
·
Jul 02

Hansoh Pharma's HS-20136-2 Injection Receives NMPA Approval for Clinical Trials

Stock News
·
Jul 02

Hansoh Pharma Says China NMPA Clears Hs-20136-2 Injection for Clinical Trials in Type 2 Diabetes

Reuters
·
Jul 02

Hansoh Pharmaceutical - Clinical Trial Approvals for Hs-20136-2 Injection Issued- by Nmpa

THOMSON REUTERS
·
Jul 02

Hansoh Pharmaceutical Group Stock Rises 6.4% in Hong Kong

Dow Jones
·
Jul 02

Movement Alert|Hansoh Pharmaceutical Rises 6.01% in Regular Trading, Pemosatide Injection Approval Coupled with Pharma Sector Rally

Market Focus
·
Jul 02

Hansoh Pharmaceutical Group Stock Falls 2.3% in Hong Kong

Dow Jones
·
Jun 30

Movement Alert|Hansoh Pharmaceutical Falls 3.03% in Regular Trading, Pharmaceutical Sector Under Broad Selling Pressure

Market Focus
·
Jun 30